Hengrui Pharmaceutical (01276): SHR-A2009 for injection obtained drug clinical trial approval notice

Zhitongcaijing · 09/02/2025 12:49

Zhitong Finance App News, Hengrui Pharmaceutical (01276) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration to issue the “Drug Clinical Trial Approval Notice” on SHR-A2009 for injectable use, and will conduct clinical trials in the near future.

SHR-A2009 for injection is an antibody-drug conjugate targeting HER3. It can specifically bind to HER3 on the surface of tumor cells, then be endocytosed into cells and transported to lysosomes. Water releases free toxins and kills tumor cells. No similar drug has been approved for marketing in the world.